You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Remove Australian Register of Therapeutic Goods (ARTG) filter Australian Register of Therapeutic Goods (ARTG) (1)
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Remove Medical devices/IVDs filter Medical devices/IVDs (55)
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (3) Apply Therapeutic goods regulation filter
- (-) Remove Advertising filter Advertising
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Medical devices/IVDs filter Medical devices/IVDs
- (-) Remove Australian Register of Therapeutic Goods (ARTG) filter Australian Register of Therapeutic Goods (ARTG)
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Medicinal cannabis filter Medicinal cannabis
Discussion paper on potential for mandatory reporting of medical device adverse events by healthcare facilities in Australia
Closed on 13 December 2021
Consultation on Draft Guidance: Assistive Technologies and the Therapeutic Goods (Excluded Goods) Determination 2021
Closed on 22 October 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Melatonin
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
Closed on 17 September 2021
Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen
Closed on 17 September 2021
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Proposed refinements to the regulation of medical devices that are substances introduced into the human body via a body orifice or applied to the skin
Closed on 13 August 2021
Proposed refinements to the regulation of personalised medical devices
Closed on 14 July 2021
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021